Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) connected to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the notification of ADS allocations to specific individuals on August 8, 2013, at a price of $51.66 per ADS.
Important Facts for Investors
- Transaction Type: Notification of notional ADS increases within the GSK 401K plan.
- Transaction Date: August 8, 2013.
- Price per ADS: $51.66.
- Individuals Affected: Dr M M Slaoui (11 ADSs), Dr K Slaoui (10 ADSs), Mr W C Louv (16 ADSs), and Mrs D P Connelly (1 ADS).
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).